Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

Market Cap	11.23B +110.5%
Revenue (ttm)	1.33B +1.7%
Net Income	241.37M -3.4%
EPS	1.37 -3.3%
Shares Out	174.35M
PE Ratio	46.95
Forward PE	42.64
Dividend	0.43 (0.65%)
Ex-Dividend Date	Jun 11, 2025

Volume	1,265,559
Average Volume	2,401,889
Open	65.77
Previous Close	66.51
Day's Range	64.25 - 66.88
52-Week Range	29.89 - 73.66
Beta	0.26
RSI	52.74
Earnings Date	Apr 22, 2026

About SHA:688513

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; Apualutamide, Bosutinib, Dacomitinib, Ibrutinib, Nilotinib HCL, Nintedanib, Relugolix, and Ruxolitinib Phosphate for oncological applications; Bricarace...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 1,522
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688513

Financial Performance

In 2024, SHA:688513's revenue was 1.35 billion, an increase of 20.82% compared to the previous year's 1.12 billion. Earnings were 238.23 million, an increase of 5.15%.